SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin - Quaterly Results

03 Aug 2022 Evaluate
The sales slipped to Rs. 27324.90 millions for the June 2022 quarter as against Rs. 33141.20 millions during the year-ago period.Net Profit for the quarter ended June 2022 dipped to Rs. 1171.80  millions from Rs. 6458.70 millions  in the corresponding previous quarter.The company reported a degrowth in operating Profit to 2951.80 millions from 9895.50 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 27324.90 33141.20 -17.55 27324.90 33141.20 -17.55 117716.70 110559.30 6.47
Other Income 853.10 516.80 65.07 853.10 516.80 65.07 2169.90 1290.90 68.09
PBIDT 2951.80 9895.50 -70.17 2951.80 9895.50 -70.17 4261.30 21731.50 -80.39
Interest 198.70 148.20 34.08 198.70 148.20 34.08 734.70 406.20 80.87
PBDT 2753.10 9747.30 -71.76 2753.10 9747.30 -71.76 3526.60 21325.30 -83.46
Depreciation 1303.50 1253.60 3.98 1303.50 1253.60 3.98 5141.90 5028.30 2.26
PBT 1449.60 8493.70 -82.93 1449.60 8493.70 -82.93 -1615.30 16297.00 -109.91
TAX 277.80 2035.00 -86.35 277.80 2035.00 -86.35 271.70 3710.80 -92.68
Deferred Tax -11.60 -30.60 -62.09 -11.60 -30.60 -62.09 -306.30 82.30 -472.17
PAT 1171.80 6458.70 -81.86 1171.80 6458.70 -81.86 -1887.00 12586.20 -114.99
Equity 909.30 907.80 0.17 909.30 907.80 0.17 909.00 907.40 0.18
PBIDTM(%) 10.80 29.86 -63.82 10.80 29.86 -63.82 3.62 19.66 -81.58

Lupin Share Price

2324.25 -2.25 (-0.10%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×